EP1009232A4 - Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque - Google Patents

Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque

Info

Publication number
EP1009232A4
EP1009232A4 EP97953324A EP97953324A EP1009232A4 EP 1009232 A4 EP1009232 A4 EP 1009232A4 EP 97953324 A EP97953324 A EP 97953324A EP 97953324 A EP97953324 A EP 97953324A EP 1009232 A4 EP1009232 A4 EP 1009232A4
Authority
EP
European Patent Office
Prior art keywords
disease
risk
methods
insulin resistance
identifying patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97953324A
Other languages
German (de)
English (en)
Other versions
EP1009232A1 (fr
Inventor
Fred I Chasalow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of EP1009232A1 publication Critical patent/EP1009232A1/fr
Publication of EP1009232A4 publication Critical patent/EP1009232A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
EP97953324A 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque Withdrawn EP1009232A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3450496P 1996-12-24 1996-12-24
US34504P 1996-12-24
US3741797P 1997-02-21 1997-02-21
US37417P 1997-02-21
PCT/US1997/023481 WO1998027813A1 (fr) 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque

Publications (2)

Publication Number Publication Date
EP1009232A1 EP1009232A1 (fr) 2000-06-21
EP1009232A4 true EP1009232A4 (fr) 2002-06-12

Family

ID=26711037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97953324A Withdrawn EP1009232A4 (fr) 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque

Country Status (5)

Country Link
EP (1) EP1009232A4 (fr)
JP (1) JP2001508770A (fr)
AU (1) AU5709698A (fr)
CA (1) CA2276149A1 (fr)
WO (1) WO1998027813A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220111011A1 (en) * 2020-10-13 2022-04-14 Betavive Ltd. Method and Compounds for Treating Diabetes and Associated Metabolic Diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHASALOW F I ET AL: "CORRELATION OF IGF-2 CONCENTRATIONS WITH INSULIN REQUIREMENTS IN DIABETES MELLITUS", PEDIATRIC RESEARCH, WILLIAMS AND WILKINS, BALTIMORE, MD,, US, vol. 37, no. 4, PART 2, 1994, pages 86A, XP001024844, ISSN: 0031-3998 *
FROESCH ER ET AL.: "Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance", DIABETES & METABOLISM (PARIS), vol. 22, 1996, pages 261 - 267, XP001041950 *
FROST RA ET AL.: "Wasting in the acquired immune deficiency syndrome is linked associated with multiple defects in serum inulin-like growth factor system", CLINICAL ENDOCRINOLOGY, vol. 44, May 1996 (1996-05-01), pages 501 - 514, XP001024899 *
JOHANSSON JO ET AL.: "Growth hormone deficient adults are insulin-resistant", METABOLISM, vol. 44, no. 9, 1995, pages 1126 - 1129, XP001041622 *
JUÁREZ-AGUILAR E ET AL.: "22-kDa and 20-kDa isoforms show differential effects when assayed in 3T3-F442A and T3-F442A/C4 adipiocytes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, vol. 217, no. 1, 1995, pages 28 - 33, XP001024865 *
See also references of WO9827813A1 *

Also Published As

Publication number Publication date
WO1998027813A1 (fr) 1998-07-02
CA2276149A1 (fr) 1998-07-02
AU5709698A (en) 1998-07-17
EP1009232A1 (fr) 2000-06-21
JP2001508770A (ja) 2001-07-03

Similar Documents

Publication Publication Date Title
IL116847A0 (en) Diagnostic imaging contrast agents and methods for extending the blood retention thereof
IL120935A0 (en) Medical apparatus for facilitating blood circulation in the lower limbs
EP0782439A4 (fr) Revetement biocompatible, dispositif medical utilisant ce revetement et procedes associes
IL125756A (en) Catheter for use in surgery
EP0800795A4 (fr) Appareil medical de coagulation
IL139030A0 (en) Therapeutic angiogenic factors and methods for their use
EP1065978A4 (fr) Dispositif therapeutique implantable et methode afferente
GB2324734B (en) Catheter and needle assemblies
EP1056514A4 (fr) Implant endoluminal a capacites therapeutique et diagnostique
HUP0002657A3 (en) Clinical and/or surgical training apparatus
HK1010498A1 (en) Oriented medical tubing
EG21712A (en) Treatment of insulin resistance
AU3887599A (en) Medical analysis and treatment method and system
GB9425493D0 (en) Modified cannula
ZA987174B (en) Procedures and materials for conferring disease resistance in plants.
ZA97825B (en) Method and system for identifying at risk patients diagnosed with depression.
HK1045269A1 (zh) 有關血液透析及治療
EP0921803A4 (fr) Procede permettant de prevenir et de traiter une infection pestivirale et les maladies qui y sont associees
EP1009232A4 (fr) Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque
ZA953237B (en) Medical treatment
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
GB9421223D0 (en) Tissue imaging in gene therapy
AU3159297A (en) Device for treating the human body with heat
GB9626265D0 (en) Medical treatment
PL104284U1 (en) Medical syringe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SUPERGEN, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20020503

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 37/18 A, 7A 61K 38/00 B, 7A 61K 38/28 B, 7A 61K 38/27 B

17Q First examination report despatched

Effective date: 20021120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030401